PANDA: The Newest Product at EpiVax

PANDA: The Newest Product at EpiVax

Revolutionizing Risk Assessment: Generic Peptide Drugs and Their Impurities EpiVax has been awarded a $1 million contract from the Food and Drug Administration (FDA) to demonstrate and validate the best practices and procedures for assessing generic peptide drugs and...
Bamako, not Timbuktu

Bamako, not Timbuktu

The beginning, and why we go : A look back at to February 2003, trip to Bamako A Travelogue by Annie De Groot, M.D. Dr. Annie De Groot and her associate Julie McMurry traveled to Bamako, Mali in January in 2003 to visit an AIDS vaccine clinical trial site. In 2002,...
Immune Engineering Cas9: Yes We Can!

Immune Engineering Cas9: Yes We Can!

The CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR-associated nuclease-9) system has been a model of great promise in the gene therapy research community since 2012. It was initially discovered as the adaptive immune system of certain...